Pemetrexed 100mg Injection

Pemetrexed 100mg Injection is a sophisticated multi-targeted antifolate antineoplastic agent designed to disrupt the fundamental metabolic processes required for cancer cell replication. Unlike simpler antimetabolites that target a single enzyme, this medication inhibits three critical enzymes involved in folate metabolism: thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). By blocking these enzymes, the drug effectively shuts down the de novo synthesis of thymidine and purine nucleotides, which are the essential building blocks for DNA and RNA. Without these components, malignant cells cannot repair or replicate their genetic material, leading to cell cycle arrest and apoptosis (programmed cell death). Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for treating thoracic malignancies, offering a potent yet manageable backbone for combination chemotherapy regimens.

The 100mg vial is a specialized dosing unit primarily used for pediatric patients, dose modifications, or to precisely augment the standard 500mg vials to reach a patient’s exact body surface area (BSA) requirement. The standard dosing regimen is 500 mg/m² administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. The 100mg strength ensures minimal drug wastage during the compounding process, allowing pharmacy teams to prepare the exact prescribed volume. It is critical that this medication is administered only after the patient has received the mandatory “pre-medication” protocol of folic acid and vitamin B12 to mitigate systemic toxicity.

Indications and Uses of Pemetrexed 100mg Injection

Pemetrexed 100mg Injection is commonly prescribed for the specialized management of the following malignancies:

• Non-Squamous Non-Small Cell Lung Cancer (NSCLC): It is indicated in combination with cisplatin for the first-line treatment of patients with locally advanced or metastatic non-squamous NSCLC. It is also used as a single agent for maintenance therapy or second-line treatment.
• Malignant Pleural Mesothelioma: The medication is indicated in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery.

Key Features of Pemetrexed 100mg Injection

• Multi-Enzyme Target: The primary feature of Pemetrexed 100mg Injection is its ability to inhibit three distinct pathways in nucleotide synthesis, making it harder for cancer cells to develop resistance.
• Histology-Specific Efficacy: It shows superior efficacy specifically in “non-squamous” cell types, allowing for a personalized medicine approach in lung cancer treatment.
• 10-Minute Infusion: The rapid administration time significantly reduces the clinical burden for patients compared to multi-hour chemotherapy infusions.
• Precision 100mg Unit: The smaller vial size facilitates accurate dosing and cost-effective preparation in the oncology pharmacy.
• Maintenance Potential: Its manageable toxicity profile allows for long-term “switch maintenance” therapy to keep the disease in remission.

Storage for Pemetrexed 100mg Injection

To preserve the pharmacological stability and ultimate potency of the active ingredients, Pemetrexed 100mg Injection (unopened vials) should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Once reconstituted with 0.9% Sodium Chloride, the chemical stability of the solution is limited. The reconstituted solution and the subsequent infusion solution should be used within 24 hours if stored under refrigeration (2°C to 8°C). It is vital to discard any unused portion after 24 hours. Store the medication in a secure, professional medical environment strictly out of the reach of children.

Safety Warnings for Pemetrexed 100mg Injection

The administration of Pemetrexed 100mg Injection carries a strict requirement for Pre-medication Supplementation. To reduce the risk of severe hematologic and gastrointestinal toxicity, patients must take Folic Acid (350–1000 mcg daily) and receive Vitamin B12 injections (1000 mcg every 3 cycles) starting at least one week before the first dose.

Myelosuppression: The drug can cause severe neutropenia, thrombocytopenia, and anemia. A Complete Blood Count (CBC) must be monitored prior to each dose. Renal Function: Pemetrexed is primarily excreted by the kidneys; it should not be administered to patients with a creatinine clearance (CrCl) less than 45 mL/min. NSAID Interaction: Patients must avoid taking ibuprofen or other NSAIDs for 2 days before, on the day of, and 2 days after the infusion, as these drugs can slow pemetrexed excretion and increase toxicity.

Dermatologic Toxicity: To prevent skin rashes, patients are typically pre-treated with dexamethasone (4mg twice daily) for three days starting the day before the infusion. Pemetrexed 100mg Injection can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and supplementation protocols, healthcare providers can safely maximize the survival benefits of Pemetrexed 100mg Injection.